Gritstone bio, Inc. (NASDAQ:GRTS – Get Rating) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 3,960,000 shares, an increase of 25.3% from the April 30th total of 3,160,000 shares. Based on an average trading volume of 1,300,000 shares, the short-interest ratio is currently 3.0 days.
Several large investors have recently bought and sold shares of the company. Invesco Ltd. increased its stake in Gritstone bio by 102.0% in the third quarter. Invesco Ltd. now owns 412,938 shares of the company’s stock valued at $4,460,000 after acquiring an additional 208,516 shares during the period. HighVista Strategies LLC bought a new stake in Gritstone bio in the third quarter valued at about $156,000. Deep Track Capital LP bought a new stake in Gritstone bio in the fourth quarter valued at about $22,785,000. Goldman Sachs Group Inc. increased its stake in Gritstone bio by 86.6% in the third quarter. Goldman Sachs Group Inc. now owns 62,825 shares of the company’s stock valued at $679,000 after acquiring an additional 29,160 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new stake in Gritstone bio in the fourth quarter valued at about $896,000. Institutional investors own 67.73% of the company’s stock.
Separately, HC Wainwright cut their target price on shares of Gritstone bio from $15.00 to $12.00 in a research report on Monday, May 9th.
Gritstone bio (NASDAQ:GRTS – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Gritstone bio had a negative return on equity of 56.52% and a negative net margin of 712.33%. During the same quarter in the prior year, the company posted $0.10 EPS. Equities analysts forecast that Gritstone bio will post -1.51 earnings per share for the current fiscal year.
About Gritstone bio (Get Rating)
Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
- Get a free copy of the StockNews.com research report on Gritstone bio (GRTS)
- There Are Cracks In The Paint At Sherwin-Williams
- 3 Outperforming Energy Stocks with More in the Tank
- American Well Corporation Stock May Well Be Bottoming
- Three Beaten Down Stocks The Insiders Are Buying
- Should Medtronic Make the Cut For Your Recovery Watchlist?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Gritstone bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone bio and related companies with MarketBeat.com's FREE daily email newsletter.